Extrapolating in vitro metabolic interactions to isolated perfused liver: Predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4406-4426

  Haddad, Sami ^a   Poulin, Patrick ^b   Funk, Christoph ^c  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b Non Clinical Drug Safety ^*  (Canada)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

DDI; Drug interaction; In vitro in vivo extrapolation; Isolated perfused liver; IVIVE; Liver model; Metabolic clearance; Metabolism in vitro; Microsomes; PBPK modeling

Indexed keywords

BUFURALOL; BUNITROLOL; CYTOCHROME P450; CYTOCHROME P450 2D1; CYTOCHROME P450 2D2; DEBRISOQUINE; ISOENZYME; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; IN VITRO STUDY; LIVER MICROSOME; LIVER PERFUSION; LIVER SINUSOID; MATHEMATICAL MODEL; NONHUMAN; PARTITION COEFFICIENT; QUANTITATIVE ANALYSIS; RAT; SIMULATION; TIME; VALIDATION PROCESS;

EID: 77957357276     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22136     Document Type: Article

References (61)

1. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. 2000. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426.
2. Kanamitsu S, Ito K, Sugiyama Y. 2000. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343.
3. Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y. 2000. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab Dispos 28:467-474. (Pubitemid 30185686)
4. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. 2000. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 55:843-852.
5. Kishimoto W, Takano J, Senda C, Ishiguro N, Sakai K, Igarashi T. 2000. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 23:1027-1032.
6. Kohl C, Steinkellner M. 2000. Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 28:161-168.
7. Schmider J, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ. 1999. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 31:545-560.
8. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI. 1998. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo. J Pharm Sci 87:1184-1189.
9. McLure JA, Miners JO, Birkett DJ. 2000. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
10. Obach RS. 1996. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24:1047-1049.
11. Obach RS. 1997. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
12. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
13. Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. 2001. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 18:622-631.
14. Chien JY, Lucksiri A, Ernest CS II, Gorski JC, Wrighton SA, Hall SD. 2006. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 34:1208-1219.
15. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. 2005. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
16. Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. 2007. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693.
17. Schneider G, Coassolo P, Lave T. 1999. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J Med Chem 42:5072-5076.
18. Rowland M, Balant L, Peck C. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 6:E6.
19. Jones HM, Parrott N, Ohlenbusch G, Lave T. 2006. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet 45:1213-1226.
20. Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, Edginton AN. 2007. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 4:13.
21. Bjorkman S, Wada DR, Berling BM, Benoni G. 2001. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 90:1226-1241.
22. Bjorkman S. 2005. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br J Clin Pharmacol 59:691-704.
23. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. 2000. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426.
24. Cong D, Doherty M, Pang KS. 2000. A new physiologically based, segregated-flow model to explain route dependent intestinal metabolism. Drug Metab Dispos 28:224-235.
25. Ploeger B, Mensinga T, Sips A, Meulenbelt J, DeJongh J. 2000. A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 17:1516-1525. (Pubitemid 32217561)
26. Peters SA. 2008. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 47:245-259.
27. Fenneteau F, Poulin P, Nekka F. 2009. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 99:486-514. (E-pub ahead of print).
28. Haddad S, Charest-Tardif G, Tardif R, Krishnan K. 2000. Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol Appl Pharmacol 167:199-209.
29. Haddad S, Tardif R, Charest-Tardif G, Krishnan K. 1999. Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. Toxicol Appl Pharmacol 161:249-257.
30. Tardif R, Charest-Tardif G, Brodeur J, Krishnan K. 1997. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol Appl Pharmacol 144:120-134.
31. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
32. Peters SA. 2008. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47:261-275.
33. Paine SW, Parker AJ, Gardiner P, Webborn PJH, Riley RJ. 2008. Prediction of the pharmacokinetics of atorvastatin, cerivastatin and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365-1374.
34. Rowland M, Tozer M. 1995. Clinical pharmacokinetics: Concepts and applications. 3rd edition. Baltimore: Lippincott Williams & Wilkins. p 608.
35. Gabrielsson J, Weiner D. 1997. Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications. Stockholm: Swedish Pharmaceutical Press. p. 454.
36. Krishnan K, Andersen ME, Clewell HJ III, Yang RSH. 1994. Physiologically based pharmacokinetic modeling of chemical mixtures. In: Yang RSH, editor. Toxicology of mixtures. New York: Academic Press. pp 399-437.
37. Andersen ME, Eklund CR, Mills JJ, Barton HA, Birnbaum LS. 1997. A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s. Toxicol Appl Pharmacol 144:135-144.
38. Houston JB, Carlile DJ. 1997. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
39. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
40. Segel IH, editor. 1993. Rapid equilibrium partial and mixed type inhibition. In: Enzyme kinetics. New York: Wiley Interscience. pp 161-206.
41. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
42. Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Lawrence XY. 2007. Biopharmaceutics classification of selected betablockers: Solubility and permeability class membership. Mol Pharm 4:608-614.
43. Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL. 1979. The metabolism of 14C-debrisoquine in man. Br J Clin Pharmacol 7:257-266.
44. Eckert M, Cocco G, Strozzi C, Heizmann P, Sfrisi S. 1983. Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients. Eur J Clin Pharmacol 24:479-484.
45. Dohan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CS, Adkison KK, Polli JW. 2002. Passive permeability and p-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. Eur J Pharmacol Exp Ther 303:1029-1037.
46. Omura T, Sato R. 1964. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:3137-3142.
47. Berry MN, Friend DS. 1969. High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study. J Cell Biol 43:506-520.
48. Goldlin CR, Boelsterli UA. 1991. Reactive oxygen species and non-peroxidative mechanisms of cocaine-induced cytotoxicity in rat hepatocyte cultures. Toxicology 69:79-91.
49. Lin JH, Lu AY. 2001. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567.
50. Schwab D, Stieger B, Hagenbuch B, Meier PJ, Gerok W, Kurz G. 1997. Uptake of 3 alpha, 7 alpha, 12 alpha-trihydroxy-24- nor-5 beta-cholan-23-sulfonate into isolated rat hepatocytes by three transport systems. J Lipid Res 38:935-948.
51. Bourne G. 1981. The metabolism of b-adrenoreceptor blocking drugs. In: Bridges JW, Chasseaud LF, editors. Progress in drug metabolism. New York: John Wiley & Sons Ltd. pp 77-110.
52. Chow T, Imaoka S, Hiroi T, Funae Y. 1999. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos 27:188-192.
53. Yamamoto Y, Tasaki T, Nakamura A, Iwata H, Kazusaka A, Gonzalez FJ, Fujita S. 1998. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: Importance of CYP2D1 and CYP2D2. Pharmacogenetics 8:73-82.
54. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S, Imaoka S, Funae Y. 1992. Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab Dispos 20:367-373.
55. Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, Edwards RJ. 1999. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357-366.
56. Poirier A, Lavé T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP, Funk C. 2008. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos 36:2434-2444.
57. Kwon Y, Morris ME. 1997. Membrane transport in metabolic clearance of drugs: II: Zonal distribution patterns of concentration dependent transport and elimination processes. Pharm Res 14:780-785.
58. Nestorov I. 2001. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 120:411-420.
59. Varkonyi P, Bruckner JV, Gallo JM. 1995. Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations. J Pharm Sci 84:381-384.
60. Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F. 2009. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modelling: Model structure and parameters determination. Theor Biol Med Model 6:2-14. [Epub ahead of print].
61. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171. (Pubitemid 27191615)